课题基金 / 基金详情

Mechanisms of Heterocellular Signaling at the Myoendothelial Junction

Mechanisms of Heterocellular Signaling at the Myoendothelial Junction
肌内皮连接处的异细胞信号传导机制
批准号:
9249957
负责人:
Brant E Isakson
金额:
$52.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-01-01 至 2019-03-31

项目摘要

项目成果

Brant E Isakson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We have recently discovered that hemoglobin � is enriched in myoendothelial junctions, the anatomical location where endothelial cells and smooth muscle cells make contact in the resistance arteries. This was a significant finding because it demonstrated that hemoglobin � had an important and active role outside of erythrocytes. This protein is one of only a few truly polarized proteins to be localized to endothelial-derived myoendothelial junctions, and the siRNA-induced decrease in the amount of the protein significantly altered arterial reactivity, including constriction to phenylephrine and dilation to acetylcholine. The mechanism we derived was based on evidence indicating that monomeric hemoglobin � is a potent scavenger of nitric oxide, and that endothelial nitric oxide synthase (eNOS) and hemoglobin � were found to be in a macromolecular complex. Based on this work, as well as a plethora of strong preliminary data, we hypothesize that hemoglobin � at the myoendothelial junction is a novel regulator of nitric oxide signaling which can impact blood pressure regulation. We will test this hypothesis using two specific aims: 1.) investigate the effects of endothelial hemoglobin a gene ablation/over-expression on arterial function and 2.) elucidate how AHSP and eNOS regulate hemoglobin � expression and dioxygenase activity at the MEJ. These aims will be elucidated using studies focused first on a floxed hemoglobin � mouse as well as a hemoglobin a over-expressing mouse to determine the effects of deletion/over-expression of this protein in endothelium on arterial reactivity, whole tissue blood flow, peripheral resistance and blood pressure. In addition, a human model of the disease alpha thalassemia where 2 alleles of hemoglobin a are deleted will be used to study the effects of this genome-wide heterozygous deletion on the vasculature. Next we will investigate how the hemoglobin � chaperone hemoglobin � stabilizing protein (AHSP) may traffic hemoglobin � to the myoendothelial junction or act directly as a regulator of the hemoglobin a redox state, altering the ability of nitric oxide to bind. The sum of this proposal unites and builds on the dat obtained from our previous R01 by allowing us for the first time to ask the direct question as to the function of the myoendothelial junction in intact animals. Indeed, we believe part of the answers could provide the basis for a completely new understanding of blood pressure control by the peripheral vasculature, as well as the derivation of unexplored pharmacological targets for control of hypertension.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1089/ars.2008.2115
发表时间: 2009-02
期刊: Antioxidants & redox signaling
影响因子: 6.6
作者: [Brisset AC, Isakson BE, Kwak BR]
通讯作者: Kwak BR
DOI: 10.1089/ars.2016.6954
发表时间: 2017-05-01
期刊: Antioxidants & redox signaling
影响因子: 6.6
作者: [Kuhn V, Diederich L, Keller TCS 4th, Kramer CM, Lückstädt W, Panknin C, Suvorava T, Isakson BE, Kelm M, Cortese-Krott MM]
通讯作者: Cortese-Krott MM
DOI: 10.1161/circresaha.116.309866
发表时间: 2016-11-11
期刊: Circulation research
影响因子: 20.1
作者: [Liu S, DeLalio LJ, Isakson BE, Wang TT]
通讯作者: Wang TT
DOI: 10.1159/000338758
发表时间: 2012
期刊: Journal of vascular research
影响因子: 1.7
作者: [Lohman AW, Billaud M, Straub AC, Johnstone SR, Best AK, Lee M, Barr K, Penuela S, Laird DW, Isakson BE]
通讯作者: Isakson BE
20
    Purinergic Regulation of Veinous Endothelial Permeability
    • 批准号:
      10735035
    • 项目类别:
    • 资助金额:
      $67.27万
    • 财政年份:
      2018
    • 负责人:
      Brant E Isakson
    • 依托单位:
    Pannexin 1 and sympathetic vasoconstriction
    • 批准号:
      10407614
    • 项目类别:
    • 资助金额:
      $40.58万
    • 财政年份:
      2014
    • 负责人:
      Brant E Isakson
    • 依托单位:
    Pannexin 1 and sympathetic vasoconstriction
    • 批准号:
      10625327
    • 项目类别:
    • 资助金额:
      $40.58万
    • 财政年份:
      2014
    • 负责人:
      Brant E Isakson
    • 依托单位:
    Pannexin 1 and sympathetic vasoconstriction
    • 批准号:
      10200123
    • 项目类别:
    • 资助金额:
      $40.58万
    • 财政年份:
      2014
    • 负责人:
      Brant E Isakson
    • 依托单位:
    海外基金